AstraZeneca

News

AZ chalks up another win for Imfinzi, Lynparza duo

AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lea

News

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

Farxiga back on level pegging in heart failure

The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar

News

Lynparza set for narrow prostate cancer use after FDA vote

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.

News

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d

AZ chalks up another win for Imfinzi, Lynparza duo

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca builds in cancer ADCs again, with LaNova deal

Farxiga back on level pegging in heart failure

Lynparza set for narrow prostate cancer use after FDA vote

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

Lilly's rival to Novo's new Awiqli insulin gets FDA approval

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks